WO2012024611A1 - Procédés de traitement de la sarcopénie et de la fragilité - Google Patents

Procédés de traitement de la sarcopénie et de la fragilité Download PDF

Info

Publication number
WO2012024611A1
WO2012024611A1 PCT/US2011/048465 US2011048465W WO2012024611A1 WO 2012024611 A1 WO2012024611 A1 WO 2012024611A1 US 2011048465 W US2011048465 W US 2011048465W WO 2012024611 A1 WO2012024611 A1 WO 2012024611A1
Authority
WO
WIPO (PCT)
Prior art keywords
beta
alanine
subject
muscle
frailty
Prior art date
Application number
PCT/US2011/048465
Other languages
English (en)
Inventor
Roger Harris
John Wise
Original Assignee
Natural Alternatives International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Alternatives International, Inc. filed Critical Natural Alternatives International, Inc.
Publication of WO2012024611A1 publication Critical patent/WO2012024611A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid

Abstract

La présente invention concerne des procédés comprenant l'administration de béta-alanine afin de traiter des troubles musculaires et d'améliorer la fonction musculaire. Parmi lesdits procédés figurent des procédés permettant le maintien de la force et de la fonction musculaire (par exemple chez les personnes âgées), l'inversion ou la prévention de la fragilité ou du déclin fonctionnel lié à l'âge chez les personnes âgées, l'inversion ou la prévention de la sarcopénie, et le traitement de la détérioration musculo-squelettique chez les personnes âgées.
PCT/US2011/048465 2010-08-20 2011-08-19 Procédés de traitement de la sarcopénie et de la fragilité WO2012024611A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40191910P 2010-08-20 2010-08-20
US61/401,919 2010-08-20
US201161503818P 2011-07-01 2011-07-01
US61/503,818 2011-07-01

Publications (1)

Publication Number Publication Date
WO2012024611A1 true WO2012024611A1 (fr) 2012-02-23

Family

ID=45605444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048465 WO2012024611A1 (fr) 2010-08-20 2011-08-19 Procédés de traitement de la sarcopénie et de la fragilité

Country Status (1)

Country Link
WO (1) WO2012024611A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT513274A4 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
WO2014117176A1 (fr) * 2013-01-28 2014-07-31 Lopez Hector L Procédés d'amélioration de la tolérance à β-alanine, de sa pharmacodynamie et de son efficacité et son utilisation
WO2014200332A1 (fr) 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
WO2015048340A3 (fr) * 2013-09-25 2015-10-08 Pronutria, Inc. Compositions et formulations pour le traitement des maladies de malabsorption et les affections inflammatoires des voies gastro-intestinales, leurs procédés de production et d'utilisation
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US9907331B2 (en) 2013-03-08 2018-03-06 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9943525B2 (en) 2014-10-06 2018-04-17 Samsung Electronics Co., Ltd. Composition for reducing cell senescence comprising Rho-kinase inhibitor and use thereof
WO2018091564A1 (fr) * 2016-11-16 2018-05-24 Fresenius Kabi Deutschland Gmbh Composition nutritionnelle destinée à être utilisée en thérapie de patients atteints de sarcopénie et/ou de fragilité ou de patients pré-sarcopéniques et/ou pré-fragiles
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
CN108455575A (zh) * 2018-02-19 2018-08-28 桂林理工大学 一种还原石墨烯的制备方法
WO2020092451A1 (fr) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés
US20200390793A1 (en) * 2017-11-21 2020-12-17 Societe Des Produits Nestle S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN114558104A (zh) * 2020-11-27 2022-05-31 利统股份有限公司 用于治疗抽筋和痉挛的配制物
US11684074B2 (en) 2017-05-12 2023-06-27 Axiom Foods, Inc. Rice products and systems and methods for making thereof
US11969411B2 (en) 2016-04-19 2024-04-30 Axcess Global Sciences, Llc Administration of berberine metabolites

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242727A1 (en) * 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20090181903A1 (en) * 2008-01-11 2009-07-16 Robert Wolfe Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242727A1 (en) * 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20090181903A1 (en) * 2008-01-11 2009-07-16 Robert Wolfe Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEFFEN ET AL.: "Age- and Gender-Related Test Performance in Community-Dwelling Elderly People: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and Gait Speeds", PHYSICAL THERAPY, vol. 82, no. 2, February 2002 (2002-02-01), pages 128 - .137 *
STOUT ET AL.: "The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): a double-blind randomized study.", J INT SOC SPORTS NUTR, vol. 5, no. 21, 7 November 2008 (2008-11-07), pages 1 - 6 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
AT513274B1 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
AT513274A4 (de) * 2012-11-02 2014-03-15 Lukas Lenhart Nahrungsergänzungsmittel
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
WO2014117176A1 (fr) * 2013-01-28 2014-07-31 Lopez Hector L Procédés d'amélioration de la tolérance à β-alanine, de sa pharmacodynamie et de son efficacité et son utilisation
US20160271260A1 (en) * 2013-01-28 2016-09-22 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of beta-alanine and use therefor
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9907331B2 (en) 2013-03-08 2018-03-06 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US10251415B2 (en) 2013-03-08 2019-04-09 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9961932B2 (en) 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
WO2014200332A1 (fr) 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
US11357824B2 (en) 2013-09-25 2022-06-14 Axcella Health Inc. Nutritive polypeptides and formulations thereof, and methods of production and use thereof
US9878004B2 (en) 2013-09-25 2018-01-30 Axcella Health Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
WO2015048340A3 (fr) * 2013-09-25 2015-10-08 Pronutria, Inc. Compositions et formulations pour le traitement des maladies de malabsorption et les affections inflammatoires des voies gastro-intestinales, leurs procédés de production et d'utilisation
US10463711B2 (en) 2013-09-25 2019-11-05 Axcella Health Inc. Nutritive polypeptides and formulations thereof, and methods of production and use thereof
EP3006028B1 (fr) * 2014-10-06 2020-01-15 Samsung Electronics Co., Ltd Composition permettant la réduction de la sénescence cellulaire comprenant un inhibiteur de rho-kinase et son utilisation
US9943525B2 (en) 2014-10-06 2018-04-17 Samsung Electronics Co., Ltd. Composition for reducing cell senescence comprising Rho-kinase inhibitor and use thereof
US9827217B2 (en) 2015-08-25 2017-11-28 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US10512623B2 (en) 2015-08-25 2019-12-24 Rgenix, Inc. Pharmaceutically acceptable salts of B-Guanidinopropionic acid with improved properties and uses thereof
US11969411B2 (en) 2016-04-19 2024-04-30 Axcess Global Sciences, Llc Administration of berberine metabolites
CN109982585A (zh) * 2016-11-16 2019-07-05 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
EP3711493A1 (fr) * 2016-11-16 2020-09-23 Fresenius Kabi Deutschland GmbH Composition nutritionnelle à utiliser dans la thérapie de patients atteints de fragilité et/ou de sarcopénie ou de pré-sarcopénie ou de fragilité précoce
CN109982585B (zh) * 2016-11-16 2024-03-15 费森尤斯卡比德国有限公司 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物
WO2018091564A1 (fr) * 2016-11-16 2018-05-24 Fresenius Kabi Deutschland Gmbh Composition nutritionnelle destinée à être utilisée en thérapie de patients atteints de sarcopénie et/ou de fragilité ou de patients pré-sarcopéniques et/ou pré-fragiles
US11612578B2 (en) 2016-11-16 2023-03-28 Fresenius Kabi Deutschland Gmbh Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
US9884813B1 (en) 2017-03-01 2018-02-06 Rgenix, Inc. Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof
US11684074B2 (en) 2017-05-12 2023-06-27 Axiom Foods, Inc. Rice products and systems and methods for making thereof
US20200390793A1 (en) * 2017-11-21 2020-12-17 Societe Des Produits Nestle S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN108455575A (zh) * 2018-02-19 2018-08-28 桂林理工大学 一种还原石墨烯的制备方法
WO2020092451A1 (fr) * 2018-10-29 2020-05-07 Keto Patent Group, Inc. Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés
CN114558104A (zh) * 2020-11-27 2022-05-31 利统股份有限公司 用于治疗抽筋和痉挛的配制物

Similar Documents

Publication Publication Date Title
WO2012024611A1 (fr) Procédés de traitement de la sarcopénie et de la fragilité
Tipton et al. Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise
Paddon-Jones et al. Exogenous amino acids stimulate human muscle anabolism without interfering with the response to mixed meal ingestion
US20210023096A1 (en) Nutritional Intervention for Improving Muscular Function and Strength
US20150174088A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
US20220211750A1 (en) Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof
EP3021690B1 (fr) Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
JP2006522821A (ja) 組織における無酸素性作業能力を高めるための方法及び組成物
US20230131476A1 (en) Compositions containing amino acids and methods of using such compositions for treating sarcopenia
US11173167B2 (en) Nutritional intervention for improving muscular function and strength
Serafini et al. Nutritional approach to sarcopenia
Larsen et al. Response to resistance training following immobilization—Influence of delaying post‐exercise meal
US20210393559A1 (en) Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise
US20210113501A1 (en) Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
US20230390262A1 (en) Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating sarcopenia and frailty
WO2023222706A1 (fr) Compositions comprenant une association de créatine et d'oleuropéine ou d'un métabolite de celle-ci et leur utilisation pour améliorer la fonction musculaire
Greenwood et al. Effective nutritional supplement combinations
Landis et al. 9 Nitrogenous Compounds
JP2010150263A (ja) 組織における無酸素性作業能力を高めるための方法及び組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11818844

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11818844

Country of ref document: EP

Kind code of ref document: A1